Page last updated: 2024-11-05

xanthone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Xanthones are a class of natural products characterized by a 9H-xanthen-9-one core structure. They are widely distributed in nature, particularly in plants, fungi, and bacteria. Xanthones exhibit a diverse range of biological activities, including antioxidant, anti-inflammatory, anticancer, antimicrobial, and antidiabetic properties. Their synthesis involves various pathways, often starting from polyketide precursors. The unique structural features of xanthones, including their planar aromatic system and the presence of oxygen functionalities, contribute to their biological activity. The presence of substituents on the xanthone scaffold influences their pharmacological properties. For example, hydroxylated xanthones have been found to possess potent antioxidant activity due to their ability to scavenge free radicals. Research on xanthones focuses on elucidating their biological activities, identifying potential drug candidates, and developing synthetic approaches for their production. Understanding the structure-activity relationships of xanthones is crucial for designing new and more potent therapeutic agents.'

xanthone : The parent compound of the xanthone class consisting of xanthene bearing a single oxo substituent at position 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7020
CHEMBL ID186784
CHEBI ID37647
SCHEMBL ID41161
MeSH IDM0054592

Synonyms (81)

Synonym
SDCCGMLS-0066462.P001
9-oxoxanthene
9h-xanthen-9-one
9h-xanthene, 9-oxo-
xanthone
xanthen-9-one
nsc-14978
nsc14978
wln: t c666 bo ivj
9-xanthenone
benzophenone oxide
90-47-1
diphenylene ketone oxide
e 6
genicide
xanthene, 9-oxo-
dibenzo-.gamma.-pyrone
inchi=1/c13h8o2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8
CHEBI:37647 ,
9-xanthone
dibenzo-gamma-pyrone
xanthenone
STK372481
GHL.PD_MITSCHER_LEG0.1212
xanthone, 97%
NCGC00095484-01
epa pesticide chemical code 086503
nsc 14978
caswell no. 905
einecs 201-997-7
ai3-00077
KBIO3_002891
SPECTRUM2_000052
SPECTRUM3_001884
SPBIO_000203
SPECTRUM200523
BSPBIO_003388
AKOS001213782
smr000112239
MLS002207109
bdbm50155411
CHEMBL186784 ,
AC-907/21098006
X0005
A843557
NCGC00095484-03
NCGC00095484-02
tox21_301151
dtxsid6021795 ,
cas-90-47-1
dtxcid201795
NCGC00255049-01
CCG-38356
ST024714
diphenyline ketone oxide
9749wev0ca ,
unii-9749wev0ca
FT-0645039
S2372
SCHEMBL41161
xanthene-9-one
xanthone [mi]
xanthone [usp-rs]
W-100331
STR05546
F8889-9282
mfcd00005060
xanthone, united states pharmacopeia (usp) reference standard
HMS3651G22
SR-05000002437-1
sr-05000002437
SW219800-1
BCP21155
Q421789
HY-N0126
F15407
xanthone (genicide)
SY017687
CS-0007833
EN300-20176
Z104477176

Research Excerpts

Overview

Xanthone is a phenolic compound found in a few higher plant families. It has a variety of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Xanthone glucosides are a significant branch of xanthones.

ExcerptReferenceRelevance
"Xanthone glucosides are a significant branch of xanthones."( Xanthone Glucosides: Isolation, Bioactivity and Synthesis.
Huang, Q; Wang, Y; Wu, H; Xu, H; Yuan, M; Zheng, C, 2021
)
2.79
"Xanthone is a phenolic compound found in a few higher plant families; it has a variety of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. "( Xanthone suppresses allergic contact dermatitis in vitro and in vivo.
Aye, A; Jeon, YD; Jin, JS; Song, YJ, 2020
)
3.44
"Xanthones are a group of oxygen-containing heterocyclic compounds including alpha-mangostin, gamma-mangostin, mangosteen extract, xanthone derivatives and synthetic xanthones, which provide remarkable and diverse pharmacological effects such as anticancer, antioxidant, anti-inflammatory and antimicrobial activities."( Xanthones from mangosteen (Garcinia mangostana): multi-targeting pharmacological properties.
Jindarat, S, 2014
)
3.29
"Xanthones (XH) are a class of heterocyclic compounds widely distributed in nature that hold numerous noteworthy biological and antioxidant activities. "( Characterization of 2,3-diarylxanthones by electrospray mass spectrometry: gas-phase chemistry versus known antioxidant activity properties.
Barros, AS; Barros, CM; Domingues, MR; Santos, CM; Silva, AM; Silva, EM, 2016
)
2.17
"Xanthones are a class of molecules that bind to a number of drug targets and possess a myriad of biological properties. "( Genome-based deletion analysis reveals the prenyl xanthone biosynthesis pathway in Aspergillus nidulans.
Chiang, YM; Entwistle, R; Hung, JH; Jain, S; Oakley, BR; Sanchez, JF; Wang, CC; Yaegashi, J, 2011
)
2.07

Effects

ExcerptReferenceRelevance
"Five xanthones have been isolated from Garcinia cowa Roxb. "( Xanthones of Garcinia cowa.
na Pattalung, P; Taylor, WC; Thongtheeraparp, W; Wiriyachitra, P, 1994
)
2.25

Treatment

ExcerptReferenceRelevance
"Xanthone treatment improved all indicators compared to the Pb-treated group."( Neuroprotective effects of xanthone derivative of Garcinia mangostana against lead-induced acetylcholinesterase dysfunction and cognitive impairment.
Phyu, MP; Tangpong, J, 2014
)
1.42

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic differences of mangiferin following oral administration of pure mangiferin and polyherbal formulation containing Salacia species were studied with approximately the same dose 30 mg/kg mangiferin and its distribution among the major tissue in Wistar rats."( Comparative pharmacokinetic study of mangiferin after oral administration of pure mangiferin and US patented polyherbal formulation to rats.
Agrawal, A; Dubey, GP; Inampudi, J; Kaliappan, I; Kammalla, AK; Ramasamy, MK, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Combining of xanthone with piperazine moiety resulted in obtaining of compounds with increased bioavailability after oral administration."( Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety.
Bojarski, AJ; Gunia, A; Marona, H; Pytka, K; Satała, G; Siwek, A; Szkaradek, N; Szneler, E; Waszkielewicz, AM, 2013
)
0.99
" The results indicate that the reason which delays the elimination of mangiferin and enhances its bioavailability might the interactions of the some other constituents present in the polyherbal formulation."( Comparative pharmacokinetic study of mangiferin after oral administration of pure mangiferin and US patented polyherbal formulation to rats.
Agrawal, A; Dubey, GP; Inampudi, J; Kaliappan, I; Kammalla, AK; Ramasamy, MK, 2015
)
0.42
" Its absolute bioavailability is low, with minimal oral absorption."( A Method of Effectively Improved α-Mangostin Bioavailability.
Cai, E; Hou, Y; Lei, D; Liu, S; Tang, G; Tang, Q; Wang, S; Zhang, J; Zhang, L; Zhao, Y, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
insecticideStrictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency20.00480.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.29730.006038.004119,952.5996AID1159521; AID1159523
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency52.95640.000221.22318,912.5098AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.30600.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.02820.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency20.47150.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.89170.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.16980.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency31.83264.466818.391635.4813AID1467; AID2107
aryl hydrocarbon receptorHomo sapiens (human)Potency61.13060.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.11310.001723.839378.1014AID743083
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
histone deacetylase 9 isoform 3Homo sapiens (human)Potency17.22890.037617.082361.1927AID1259364; AID1259388
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
caspase-1 isoform alpha precursorHomo sapiens (human)Potency25.11890.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.63790.001557.789015,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.63790.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Caspase-7Homo sapiens (human)Potency25.11893.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseHomo sapiens (human)IC50 (µMol)8.84000.02304.459310.0000AID1683486
Phosphoglycerate mutase 1Homo sapiens (human)IC50 (µMol)0.50000.49002.14677.2000AID1708712
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.73150.00002.37899.7700AID1888748; AID240726
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
gluconeogenesisPhosphoglycerate mutase 1Homo sapiens (human)
canonical glycolysisPhosphoglycerate mutase 1Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
bisphosphoglycerate mutase activityPhosphoglycerate mutase 1Homo sapiens (human)
phosphoglycerate mutase activityPhosphoglycerate mutase 1Homo sapiens (human)
protein bindingPhosphoglycerate mutase 1Homo sapiens (human)
hydrolase activityPhosphoglycerate mutase 1Homo sapiens (human)
protein kinase bindingPhosphoglycerate mutase 1Homo sapiens (human)
2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activityPhosphoglycerate mutase 1Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionPhosphoglycerate mutase 1Homo sapiens (human)
cytoplasmPhosphoglycerate mutase 1Homo sapiens (human)
cytosolPhosphoglycerate mutase 1Homo sapiens (human)
membranePhosphoglycerate mutase 1Homo sapiens (human)
secretory granule lumenPhosphoglycerate mutase 1Homo sapiens (human)
extracellular exosomePhosphoglycerate mutase 1Homo sapiens (human)
ficolin-1-rich granule lumenPhosphoglycerate mutase 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID398909Antifungal activity against Alternaria tenuis at 1000 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID240726Concentration required to inhibit monoamine oxidase activity by 50%2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
QSAR modeling of the MAO inhibitory activity of xanthones derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1357641Toxicity in zebra fish larvae at 5 uM after 48 hrs2018European journal of medicinal chemistry, May-10, Volume: 151Lipid reducing activity and toxicity profiles of a library of polyphenol derivatives.
AID459916Cytotoxicity against human HeLa cells after 48 hrs2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Synthesis and cancer cell cytotoxicity of substituted xanthenes.
AID1888752Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 uM after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID1683487Inhibition of Tyrosinase (unknown origin) at 150 uM using tyrosine as substrate incubated for 20 mins followed by substrate addition and measured every 10 mins for 30 mins relative to control2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID1081528Insecticidal activity against first-instar larval-stage of Spodoptera frugiperda (fall armyworm) strain corn in compound-pretreated corn leaves assessed as mortality rate at 2000 mg/kg2010Journal of agricultural and food chemistry, May-26, Volume: 58, Issue:10
Sustainable synthesis of flavonoid derivatives, QSAR study and insecticidal activity against the fall armyworm, Spodoptera frugiperda (Lep.: Noctuidae).
AID399161Antifungal activity against Drechslera oryzae at 10 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID398908Antifungal activity against Alternaria tenuis at 100 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID1683488Inhibition of Hyaluronidase (unknown origin) at 9.4 to 150 uM using hyaluronic acid as substrate incubated for 20 mins followed by substrate addition and measured after 40 mins2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID1357644Cytotoxicity against mouse 3T3L1 cells at 50 uM after 48 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, May-10, Volume: 151Lipid reducing activity and toxicity profiles of a library of polyphenol derivatives.
AID399164Antifungal activity against Fusarium oxysporum vasinfectum at 1 ppm after 144 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID398910Antifungal activity against Drechslera oryzae at 1 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID399162Antifungal activity against Drechslera oryzae at 100 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID1683485Inhibition of Elastase (unknown origin) at 150 uM using N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide as substrate at 150 uM incubated for 20 mins followed by substrate addition and measured after 40 mins relative to control2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID459915Cytotoxicity against human MCF7 cells after 48 hrs2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Synthesis and cancer cell cytotoxicity of substituted xanthenes.
AID398906Antifungal activity against Alternaria tenuis at 1 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID1708712Inhibition of PGAM1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Design, synthesis, and biological evaluation of 1,3,6,7-tetrahydroxyxanthone derivatives as phosphoglycerate mutase 1 inhibitors.
AID1683486Inhibition of Tyrosinase (unknown origin) using tyrosine as substrate incubated for 20 mins followed by substrate addition and measured every 10 mins for 30 mins2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID1357643Cytotoxicity against mouse 3T3L1 cells at 50 uM after 24 hrs by sulforhodamine B assay2018European journal of medicinal chemistry, May-10, Volume: 151Lipid reducing activity and toxicity profiles of a library of polyphenol derivatives.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID1683483Inhibition of Collagenase (unknown origin) using FALGPA as substrate at 150 uM incubated for 20 mins followed by substrate addition and measured after 60 mins relative to control2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Xanthones for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity.
AID399167Antifungal activity against Fusarium oxysporum vasinfectum at 1000 ppm after 144 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID399163Antifungal activity against Drechslera oryzae at 1000 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID698548Antihemolytic activity against hypotonic hemolysis in Wistar rat erythrocytes at 100 uM after 10 mins relative to control2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis of new chiral xanthone derivatives acting as nerve conduction blockers in the rat sciatic nerve.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID459919Binding affinity to DNA assessed as DNA intercalation at 50 uM2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Synthesis and cancer cell cytotoxicity of substituted xanthenes.
AID698547Antihemolytic activity against hypotonic hemolysis in Wistar rat erythrocytes at 0.1 to 30 uM after 10 mins2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis of new chiral xanthone derivatives acting as nerve conduction blockers in the rat sciatic nerve.
AID399165Antifungal activity against Fusarium oxysporum vasinfectum at 10 ppm after 144 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID459914Cytotoxicity against human DU145 cells after 48 hrs2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Synthesis and cancer cell cytotoxicity of substituted xanthenes.
AID399166Antifungal activity against Fusarium oxysporum vasinfectum at 100 ppm after 144 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID398907Antifungal activity against Alternaria tenuis at 10 ppm after 168 hrs at 24 hrs intervals1997Journal of natural products, May, Volume: 60, Issue:5
Evaluation of the antifungal activity of natural xanthones from Garcinia mangostana and their synthetic derivatives.
AID459920Binding affinity to DNA assessed as DNA intercalation at 250 uM2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Synthesis and cancer cell cytotoxicity of substituted xanthenes.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (312)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (1.92)18.7374
1990's30 (9.62)18.2507
2000's91 (29.17)29.6817
2010's147 (47.12)24.3611
2020's38 (12.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.07 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index158.33 (26.88)
Search Engine Supply Index2.99 (0.95)

This Compound (63.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.31%)5.53%
Reviews17 (5.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other303 (94.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]